We are live on ! Find out more
CRVS icon

Corvus Pharmaceuticals
CRVS

102 hedge funds and large institutions have $307M invested in Corvus Pharmaceuticals in 2025 Q3 according to their latest regulatory filings, with 23 funds opening new positions, 34 increasing their positions, 17 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more repeat investments, than reductions

Existing positions increased: 34 | Existing positions reduced: 17

84% more capital invested

Capital invested by funds: $167M → $307M (+$140M)

77% more first-time investments, than exits

New positions opened: 23 | Existing positions closed: 13

41% more call options, than puts

Call options by funds: $2.28M | Put options by funds: $1.62M

11% more funds holding

Funds holding: 92 → 102 (+10)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

5.36% less ownership

Funds ownership: 61.29% → 55.93% (-5.4%)

Holders
102
Holders Change
+10
Holders Change %
+10.87%
% of All Funds
1.34%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
23
Increased
34
Reduced
17
Closed
13
Calls
$2.28M
Puts
$1.62M
Net Calls
+$664K
Net Calls Change
+$972K

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$2.42M
2
State Street
State Street
Massachusetts
+$1.75M
3
Goldman Sachs
Goldman Sachs
New York
+$1.41M
4
SFM
Sphera Funds Management
Israel
+$1.15M
5
Vanguard Group
Vanguard Group
Pennsylvania
+$979K

Top Sellers

Rank Fund Capital Flow
1
DA
DCF Advisers
Connecticut
-$3.03M
2
Point72 Asset Management
Point72 Asset Management
Connecticut
-$3.01M
3
Morgan Stanley
Morgan Stanley
New York
-$1.42M
4
Marshall Wace
Marshall Wace
United Kingdom
-$807K
5
Renaissance Technologies
Renaissance Technologies
New York
-$661K
Name Holding Trade Value Shares
Change 		Change in
Stake
ACM
101
Aquatic Capital Management
Illinois
$405 +$281 +55 New
DA
102
DCF Advisers
Connecticut
– -$3.03M -757,500 Closed
Marshall Wace
103
Marshall Wace
United Kingdom
– -$807K -201,651 Closed
Renaissance Technologies
104
Renaissance Technologies
New York
– -$661K -165,188 Closed
Squarepoint
105
Squarepoint
New York
– -$554K -138,462 Closed
BCM
106
BML Capital Management
Indiana
– -$475K -118,766 Closed
Susquehanna International Group
107
Susquehanna International Group
Pennsylvania
– -$347K -67,816 Closed
Qube Research & Technologies (QRT)
108
Qube Research & Technologies (QRT)
United Kingdom
– -$176K -43,969 Closed
BCM
109
Bayesian Capital Management
New York
– -$70K -17,500 Closed
VOYA Investment Management
110
VOYA Investment Management
Georgia
– -$59.1K -14,774 Closed
SCP
111
Sender Company & Partners
New York
– -$52K -12,995 Closed
CIAM
112
Caitong International Asset Management
Hong Kong
– -$8.13K -2,032 Closed
FIA
113
FNY Investment Advisers
New York
– -$8K -2,005 Closed
Comerica Bank
114
Comerica Bank
Texas
– -$1.46K -365 Closed
Carson Wealth (CWM LLC)
115
Carson Wealth (CWM LLC)
Nebraska
– +$292 +57 New
1 2 3 4
5

CRVS Hedge Fund Activity: Q3 2025 in Review

102 of the 7,620 institutional investors tracked by Wall St. Rank reported a position in Corvus Pharmaceuticals (CRVS) for Q3 2025, worth a combined $307M — up 84% from $167M a quarter earlier.

Buyers outnumbered sellers: 23 funds opened new CRVS positions and 13 closed out — a net gain of 10 holders — while 34 added to existing stakes and 17 trimmed.

The largest buyer was BlackRock, adding an estimated $2.42M. The largest seller was DCF Advisers, exiting entirely with an estimated $3.03M sold.

  • 102 institutional investors held Corvus Pharmaceuticals (CRVS) as of Q3 2025, up from 92 in Q2 2025.
  • Funds reported $307M of Corvus Pharmaceuticals stock for Q3 2025, up 84% quarter-over-quarter.
  • 23 funds opened new Corvus Pharmaceuticals positions in Q3 2025 and 13 closed out, a net change of +10 holders.
  • The largest Corvus Pharmaceuticals buyer in Q3 2025 was BlackRock, an estimated $2.42M added.
  • The largest Corvus Pharmaceuticals seller in Q3 2025 was DCF Advisers, an estimated $3.03M sold.

Based on aggregated 13F filings for Q3 2025.